UNSPSC 51172152: Trepibutone

This classification denotes an antispasmotic agent with the molecular formula C16H22O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1187LU49Q, chemically known as 2,4,5-triethoxy-gamma-oxobenzenebutanoic acid but generally known as trepibutone, which bears US NIH Compound Identifier 5536. European Medicines Agency schedules Trepibutone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11236MIG.

UNSPSC 51172152 Trepibutone, a Commodity code, does not reflect the scope of work actually being solicited under this code in recent state and local procurement. The three recent opportunities tagged with this code involve offender drug testing services, direct-to-manufacturer pharmaceutical prescription programs, and generic multi-source pharmaceuticals distribution through wholesalers—none of which involve trepibutone as a procured product or service. The mismatch suggests either a data-entry error in the opportunity tagging or a structural misalignment between the code designation and the actual work being bought.

The code shows limited relevant recent activity. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, estimated at $600,000 over two years with optional renewals; the Texas Health and Human Services Commission issued an RFI regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026. Without clear evidence that trepibutone itself is being procured as a standalone product under this code in the current state and local market, this category warrants further due diligence to establish whether it represents an active procurement vehicle or reflects a tagging anomaly.